ArticleBreast cancer research : BCR2005
Expression analysis of candidate breast tumour suppressor genes on chromosome 16q.
Article in Breast cancer research : BCR, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 43 citations in OpenAlex.
- Genome-nanosurface interaction of titania nanotube arrays: evaluation of telomere, telomerase and NF-κB activities on an epithelial cell model.RSC advances · 2022Article
- Role of columnar cell lesions in breast carcinogenesis: analysis of chromosome 16 copy number changes by multiplex ligation-dependent probe amplification.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2018Article
- CINdex: A Bioconductor Package for Analysis of Chromosome Instability in DNA Copy Number Data.Cancer informatics · 2017Article
- Decreased expression of the CHD5 gene and its clinicopathological significance in breast cancer: Correlation with aberrant DNA methylation.Oncology letters · 2016Article
- The promoter methylation status and mRNA expression levels of CTCF and SIRT6 in sporadic breast cancer.DNA and cell biology · 2014Article
- BRAF mutation-specific promoter methylation of FOX genes in colorectal cancer.Clinical epigenetics · 2013Article
- Article
- Genetic alterations of the WWOX gene in breast cancer.Medical oncology (Northwood, London, England) · 2012Article
- Expression of the epigenetic factor BORIS (CTCFL) in the human genome.Journal of translational medicine · 2011Review
- Molecular changes in primary breast tumors and the Nottingham Histologic Score.Pathology oncology research : POR · 2009Article
- Genetic characterization of breast cancer and implications for clinical management.Journal of cellular and molecular medicine · 2009Review
- The JNK inhibitor SP600129 enhances apoptosis of HCC cells induced by the tumor suppressor WWOX.Journal of hepatology · 2008Article
- Article
- Non-operative breast pathology: lobular neoplasia.Journal of clinical pathology · 2007Review
- Infrequent mutation of ATBF1 in human breast cancer.Journal of cancer research and clinical oncology · 2007Article
- Article
- E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines.British journal of cancer · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChromosome arm 16q is the second most frequent target of loss of heterozygosity in breast cancer and is, therefore, a candidate to contain one or more classic tumour suppressor genes (TSGs). E-cadherin at 16q22 was identified as a TSG in lobular breast cancer, but TSGs in ductal breast cancer remain elusive. Several genes have been suggested as potential candidates (e.g. CBFA2T3, CTCF and WWOX) but no inactivating mutations could be identified in these genes and they thus fail to fit the classic two-hit model for a TSG. With the completion of the human transcriptome, new candidate genes can be distinguished. Besides mutational inactivation, a TSG could, at least in a subset of the tumours, be transcriptionally suppressed or even inactivated. Studying candidate genes for expression and somatic mutations could thus identify the TSGs.
methodsPossible candidates CBFA2T3, TERF2 and TERF2IP, FBXL8 and LRRC29 and FANCA were studied for insertion and deletion mutations and for expression differences using quantitative RT-PCR in a panel of tumour cell lines and primary tumours with and without loss of 16q.
resultsNone of the genes showed mutations or obvious expression differences. FANCA expression increased with tumour grade.
conclusionApparently, the underlying genetics at chromosome 16q are complex or the TSGs remain to be identified. Multiple mechanisms, such as mutations, promoter hypermethylation or haploinsufficiency, might lead to the inactivation of a TSG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.